According to the Centers for Disease Control and Prevention (CDC), arthritis was expected to surpass all other disease forms in new diagnoses by 2020. That prediction has largely proven true, as arthritis now affects millions of Americans across all age groups.

Key risk factors include:

• Obesity and high BMI
• Metabolic syndrome
• Type 2 diabetes

These metabolic conditions are strongly linked to arthritis, with population studies suggesting that up to 60% of people with diabetes or metabolic syndrome also suffer from osteoarthritis. In fact, a new subtype of osteoarthritis—metabolic osteoarthritis—is now recognized due to the strong correlation between hyperglycemia and joint degeneration.

One of the biggest challenges in diagnosing arthritis is catching it early. Traditional methods like physical exams and imaging studies often fail to identify joint damage until significant and irreversible degeneration has occurred. CTX-II, on the other hand, offers a reliable and cost-effective way to identify cartilage loss well before it appears on an X-ray or MRI.

In a study comparing young athletes:

• Runners had the highest CTX-II levels
• Rowers showed moderate levels
• Swimmers had the lowest levels

This data highlights how different types of exercise may influence cartilage stress and can help practitioners advise on safer, cartilage-preserving movement strategies.

CTX-II levels also correlate with joint pain and often increase before any visible radiographic changes, making it a valuable early warning biomarker.

Type II collagen is the most abundant form of collagen in articular cartilage, comprising 10–20% of its wet weight. In osteoarthritis, the interface between subchondral bone and articular cartilage—where type II collagen resides—is a primary site of degradation and remodeling.

In healthy joints, chondrocytes (cartilage cells) maintain a balance between degradation and repair. However, adult articular cartilage has limited regenerative ability—chondrocytes have little to no cell division, and no known stem cells exist to replace them if they die.

This makes early detection vital, especially in peri-menopausal women or individuals with metabolic syndrome, who may be at greater risk of cartilage degradation due to hormonal fluctuations and inflammation.

Several factors can contribute to elevated CTX-II levels, including:

• NSAID usage: May impair cartilage repair and matrix synthesis
• Hyperglycemia & insulin resistance: Can increase oxidative stress and advanced glycation end products
• Mechanical cartilage injury: From repetitive or high-impact exercise
• Inflammatory cytokines: Which accelerate cartilage breakdown
• Hormonal changes: Especially during perimenopause and andropause

Notably, chondrocytes possess insulin receptors, and studies show they may exhibit insulin resistance in diabetic patients, further linking metabolic dysfunction to joint deterioration.

CTX-II isn’t just diagnostic—it’s also a monitoring tool. If interventions are working, CTX-II levels may stabilize or decrease, reflecting preserved cartilage health.

Recommended Interventions for Cartilage Preservation

• Normalize body weight
• Modify diet to reduce blood sugar spikes, oxidative stress, and inflammation
• Engage in moderate, low-impact exercise (like swimming or cycling)
• Supplement with omega-3 fatty acids to reduce injury-induced OA
• Incorporate resveratrol to activate SIRT1 and support chondrocyte survival

Supportive Nutrients to Consider

• Vitamin C: Supports collagen production and healthy cartilage
• Vitamin D: Modulates inflammation
• Vitamin K: Essential for bone and cartilage mineralization

Zinc & Calcium Status

Urinary excretion of both may be elevated in knee OA patients. Xanthurenic acid binds zinc and increases excretion—it is measured on MVL’s urine and dried urine hormone profiles.

Blood Sugar & Insulin Testing

Screen for metabolic syndrome or Type 2 diabetes using profiles such as the Kraft Prediabetes Profile or Glycemic Stress Index Profile.

Hormone Testing

CTX-II and xanthurenic acid levels may increase during perimenopause. Clinicians may consider:

• 24-Hour Urine Hormone Profile

Bioidentical hormone replacement therapy (BHRT) may be considered when clinically appropriate to help protect against cartilage breakdown.

• CDC overview on arthritis prevalence and risk factors
• Search osteoarthritis and cartilage biomarker literature

Osteoarthritis is no longer considered just a disease of aging—it’s intricately linked to metabolic health, hormone balance, and lifestyle choices. By implementing CTX-II testing early, providers can:

• Detect cartilage damage before it becomes irreversible
• Personalize lifestyle, nutritional, and hormonal interventions
• Track therapeutic success over time

Practitioners: Add urinary CTX-II testing to joint-risk and metabolic-osteoarthritis workups to identify early cartilage turnover and monitor response to intervention. Contact Client Services to confirm ordering options, sample requirements (second morning vs. 24-hour), and best-fit add-on testing.

Patients: Ask your licensed provider whether urinary CTX-II testing fits your joint health, metabolic, or perimenopause-related risk profile. Meridian Valley Lab provides laboratory services only and cannot advise patients directly.

Call: 855.405.8378 | 206.209.4200

This announcement summarizes clinical concepts and emerging research on CTX-II and metabolic osteoarthritis. For a detailed reference list or supporting studies, please contact our team.